Borosil Scientific Q1 Revenue Reaches ₹107 Crore, Posts ₹4.4 Crore Net Profit YoY

Market snapshot: Borosil Scientific Limited has announced its financial performance for the first quarter of FY27, showcasing a strong turnaround in profitability. The company transitioned into positive territory, posting a consolidated net profit of ₹4.4 crore compared to a loss of ₹4.2 crore in the previous year's corresponding quarter. Consolidated revenue also rose to ₹107 crore, up from ₹96 crore YoY.

Data Snapshot

• Consolidated revenue stood at ₹107 crore for Q1 FY27, representing a growth of ≈11.46% year-on-year.
• Consolidated net profit reached ₹4.4 crore, turning around from a net loss of ₹4.2 crore in Q1 FY26.

What's Changed

• Consolidated revenue grew by ≈11.46% YoY (derived: ₹107 cr vs ₹96 cr).
• Consolidated net profitability turned positive at ₹4.4 crore from a loss of ₹4.2 crore in Q1 FY26.

Key Takeaways

• Operational turnaround was marked by reversing previous losses, indicating better cost control and pricing power.
• Revenue expanded steadily by over 11% YoY, highlighting growing demand in laboratory products and pharma packaging.
• Strong fundamental stability supports the company's mid-term growth outlook and capacity expansion plans.

SAHI Perspective

Borosil Scientific's pivot to positive territory this quarter demonstrates that the demerged entity is successfully streamlining its operations. The turnaround from a net loss of ₹4.2 crore to a net profit of ₹4.4 crore suggests robust volume growth and improved operating margins in its primary scientific and pharmaceutical packaging divisions.

Market Implications

Reversing losses and delivering double-digit revenue growth is a strong signal to the market. The stock may witness increased interest from institutional investors who favor demerged pure-plays with specialized industrial offerings.

Trading Signals

Market Bias: Bullish

The bullish bias is supported by a complete turnaround in consolidated net profit to ₹4.4 crore from a loss of ₹4.2 crore YoY, alongside an ≈11.46% increase in Q1 revenue to ₹107 crore.

Overweight: Laboratory Equipment, Pharma Packaging

Trigger Factors:

• Sustainability of the newly achieved net profit margins in upcoming quarters.
• Execution timeline of the proposed ₹250 crore fundraising activity.

Time Horizon: Near-term (0-3 months)

Industry Context

The laboratory consumables and scientific glassware industry in India is benefiting from increased domestic manufacturing and pharmaceutical sector growth. Companies with local production capabilities, such as Borosil Scientific, are well-positioned to substitute imports and expand margins as raw material supply chains stabilize.

Key Risks to Watch

• Fluctuations in global energy prices affecting glass manufacturing operations.
• Dependence on the domestic pharmaceutical sector's capital expenditures and packaging demand.

Recent Developments

The company's Board approved a fundraising proposal of up to ₹250 crore on May 20, 2026. Furthermore, on June 30, 2026, the company clarified that a recent spike in trading volume was market-driven and that no price-sensitive material information had been withheld.

Closing Insight

Borosil Scientific's Q1 results confirm its path toward sustainable growth, solidifying its position as a high-potential player in the industrial and life sciences segment.

High Performance Trading with SAHI.